12/23
02:53 pm
fold
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
Neutral
Report
BioMarin Pharmaceutical (BMRN) Stock Is Up, What You Need To Know [Yahoo! Finance]
12/23
07:06 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
Neutral
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at Citigroup Inc. from a "strong-buy" rating to a "hold" rating.
12/22
10:37 pm
fold
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]
Low
Report
Analysts Grow More Bullish on BioMarin Pharmaceuticals Inc. (BMRN) After Amicus Acquisition [Yahoo! Finance]
12/22
09:00 am
fold
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) was downgraded by analysts at TD Cowen from a "buy" rating to a "hold" rating. They now have a $14.50 price target on the stock.
12/22
08:37 am
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Citigroup Inc.. They now have a $14.50 price target on the stock, down previously from $17.00.
12/21
12:39 pm
fold
Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics Valuation After a 48.3% One Month Share Price Surge [Yahoo! Finance]
12/20
08:22 am
fold
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger [Yahoo! Finance]
Low
Report
Amicus (FOLD) Flies to 52-Week High on $5-Billion BioMarin Merger [Yahoo! Finance]
12/19
11:17 am
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "hold" rating reaffirmed by analysts at Needham & Company LLC.
12/19
10:58 am
fold
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
Low
Report
Shareholder Alert: The Ademi Firm investigates whether Amicus Therapeutics, Inc. is obtaining a Fair Price for its Public Shareholders
12/19
10:34 am
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.50 price target on the stock, down previously from $21.00.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "neutral" rating reaffirmed by analysts at Cantor Fitzgerald. They now have a $14.50 price target on the stock, down previously from $21.00.
12/19
09:26 am
fold
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
Low
Report
FOLD Stock Alert: Halper Sadeh LLC is Investigating Whether the Sale of Amicus Therapeutics, Inc. is Fair to Shareholders
12/17
09:12 am
fold
Amicus Therapeutics (NASDAQ:FOLD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $17.00 price target on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) is now covered by analysts at Citigroup Inc.. They set a "buy" rating and a $17.00 price target on the stock.
12/15
02:14 am
fold
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT [Yahoo! Finance]
Low
Report
DMX-200 ACTION3 PHASE 3 TRIAL COMPLETES RECRUITMENT [Yahoo! Finance]
12/13
07:35 pm
fold
Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook [Yahoo! Finance]
Low
Report
Why Amicus Therapeutics (FOLD) Is Up 6.6% After Bullish Analyst Upgrades On Earnings Outlook [Yahoo! Finance]
12/13
07:15 am
fold
Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy' Reco [Yahoo! Finance]
Low
Report
Amicus Therapeutics (FOLD) Soars to 52-Week High on ‘Strong Buy' Reco [Yahoo! Finance]
11/28
10:23 pm
fold
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
Low
Report
Assessing Amicus Therapeutics (FOLD) Valuation as Shares Gain 11% Over Past Month [Yahoo! Finance]
11/28
08:31 am
fold
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
Low
Report
How Strong Galafold and Pombiliti Sales Helped Amicus Therapeutics (FOLD) Surpass Expectations and Shift Its Outlook [Yahoo! Finance]
11/26
02:01 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/14
01:10 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its "sell (d-)" rating reaffirmed by analysts at
Weiss Ratings.
11/11
04:59 pm
fold
Amicus Therapeutics: Moving Towards Consistent Profitability [Seeking Alpha]
Low
Report
Amicus Therapeutics: Moving Towards Consistent Profitability [Seeking Alpha]
11/10
03:40 am
fold
A Look at Amicus Therapeutics's (FOLD) Valuation After Q3 Profitability and Rare Disease Therapy Growth [Yahoo! Finance]
Medium
Report
A Look at Amicus Therapeutics's (FOLD) Valuation After Q3 Profitability and Rare Disease Therapy Growth [Yahoo! Finance]
11/10
03:01 am
fold
Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets [Yahoo! Finance]
Medium
Report
Zacks.com featured highlights include EverQuote, Amicus, Lam Research and Cboe Global Markets EverQuote, Amicus, Lam Research and Cboe Global Markets [Yahoo! Finance]
11/6
04:27 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at JPMorgan Chase & Co. from $18.00 to $19.00. They now have an "overweight" rating on the stock.
11/5
12:25 pm
fold
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $9.00 to $11.00. They now have a "neutral" rating on the stock.
Low
Report
Amicus Therapeutics (NASDAQ:FOLD) had its price target raised by analysts at The Goldman Sachs Group, Inc. from $9.00 to $11.00. They now have a "neutral" rating on the stock.
11/4
07:00 am
fold
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates
Low
Report
Amicus Therapeutics Announces Third Quarter 2025 Financial Results and Corporate Updates